MDM2 and cancer: Taken the abovementioned issues, the critical role of p53 in cancer initiation and progression, and the recently reported failure of the promising MDM2 inhibitors, RG7112, and idasanutlin in clinical trials, there is a need for enhanced efforts into development of therapies reactivating the p53 protein family [7].